Kornimate/medical-research-clean huggingface dataset:
the role of the glutamatergic system in the extinction of conditioned reinforcement processes

Conditions: Alcohol Drinking

Summary: the aim of this project is to explore whether the extinction of cue-reactivity following a cue-exposure based intervention in volunteers with an alcohol dependence is facilitated by drugs that increase nmda-receptor function. it is hypothesised that targeted treatment with d-cycloserine prior to each extinction training session enhances the effects on cue-reactivity. further, a significant correlation between the reduction of cue-reactivity and both reduced craving and relapse probability is expected.


Eligibility criteria:
inclusion criteria: * current dsm-iv/ icd-10 diagnosis of alcohol dependence * controlled abstinence for a period of 5 to 21 days following admission to inpatient detoxification or day-clinic care * women (in childbearing age): use of a highly effective method of contraception * normal or corrected-to-normal vision * ability to provide written informed consent exclusion criteria: * diagnosis of additional axis i or ii disorders (according to dsm-iv( icd- 10 criteria) either currently or within the past 12 months (except nicotine dependence) * positive drug screening * current medication with anti-convulsive or psychotropic drugs * mri ineligibility * sensitivity to study medication as evidenced by a history of adverse drug experience * severe withdrawal symptoms (e.g. convulsions, delirium) * disposition towards experiencing convulsions/ epilepsy * history of schizophrenic disorders/ affective psychosis * neurological diseases that might affect the dopaminergic, limbic and frontal cortices or extrapyramidal motor functioning * major diseases (e.g. diabetes, liver cirrhosis, heart disease) * physical illness interfering with study procedures or affecting study outcomes * pregnancy (positive test results)/ lactation period * suicidal tendencies/ increased risk that others might be harmed -

Keywords: alcoholism d-cycloserine extinction cue-exposure
assessment of acute disease to reduce imaging costs

Conditions: Acute Coronary Syndrome; Pulmonary Embolism

Summary: overtesting for acute coronary syndrome(acs) and pulmonary embolism (pe) in low risk emergency department(ed) patients can increase exposure of nondiseased patients to radiation, intravenous contrast and anticoagulation. this project addresses question of whether quantitative pre-test probability(ptp) assessed from two validated web-based computer algorithms (the project "webtool"), can improve the diagnostic evaluation of adult patients with charted evidence of chest pain and dyspnea. after a validation phase, the main study will randomize patients to either the standard care group or the intervention group, which will receive the output of the acs and pe webtool that includes the ptp estimates of acs and pe and one of three recommendations regarding next steps: 1. no further testing, 2. exclusion with a biomarker protocol, or 3. immediate imaging +/- empiric anticoagulation.


Eligibility criteria:
inclusion criteria * adult (\>17 years) ed patient reports a history of chest discomfort and new or worsened shortness of breath or breathing difficulty, documented in the written history of present illness or review of systems. * patient must understand english or have a certified translator present. * physician has ordered or plans to order a 12-lead electrocardiogram. * patient indicates the site hospital was his or her "hospital of choice" in the event of return visit within 14 days. randomization exclusions * positive urine cocaine test. * incarceration within 14 days of enrollment. * patient elopement from medical care (i.e., patients who leave against medical advice).

Keywords: computer-derived, quantitative pretest probability (ptp) overtesting radiation intravenous contrast anticoagulation
addition of gemcitabine to pre allo-hsct conditioning for acute lymphoblastic leukemia

Conditions: Acute Lymphoblastic Leukemia, Adult

Summary: the main purpose of the project is to evaluate the disease free survival and overall survival in patients diagnosed with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation (allo-hsct) adding gemcitabine to the standard institutional conditioning regimen based on two alkylating drugs, reduced busulfan and cyclophosphamide (reduced bucy 2).

in the last decade, hematopoietic stem cell transplantation (hsct) has become an efficient strategy for the treatment of high risk acute lymphoblastic leukemias. lymphoid acute leukemias (all) are considered malignant clonal diseases of the hematopoietic stem cells, and represent a therapeutic challenge due to the high relapse rate and mortality using conventional chemotherapy regimens. many studies have shown a decrease in relapse and an increase in overall survival with allogeneic hsct, however, despite the fact that results in all have improved in the past years, achieving complete remission (cr) in approximately 75% of the patients, the relapse rate remains high and long term survival is lower than 50% depending on age and disease characteristics. on the other hand, it has been stated that relapse is higher when an allo-hsct is performed in second cr, obtaining poorer results compared to performing hsct in first cr, although better than chemotherapy alone (87% probability of relapse). it is necessary to implement strategies that increase efficiency of pre transplant conditioning regimens in patients diagnosed with all undergoing an allo-hsct in order to reduce relapse and increase overall survival. the hypothesis is that adding gemcitabine to the standard institutional conditioning regimen (reduced bucy 2) in patients with all undergoing an allo-hsct, the relapse free survival as well as the overall survival will improve, because it has been demonstrated in other malignant hematological diseases that gemcitabine plus two alkylating agents, facilitates synergism with busulfan and melphalan, inhibiting the dna damage repair and causing a higher cytotoxic effect.

Eligibility criteria:
inclusion criteria: * diagnosis of acute lymphoblastic leukemia in 2nd complete remission or primary refractory disease, candidates to hematopoietic stem cell transplantation. * hemoglobin ≥ 10 g/dl, absolute neutrophil count ≥ 1 x 103/mm3, and platelets ≥ 100,000 /µl * eastern cooperative oncology group status (ecog) ≤2 or karnofsky ≥80% * signed informed consent * left ventricular ejection fraction (lvef) \>40% * normal liver function enzyme tests * preserved renal function exclusion criteria: * patients not willing to participate or to sign the informed consent * patients who do not meet the inclusion criteria
use of hair to diagnose the presence of breast cancer

Conditions: Breast Cancer

Summary: using synchrotron x-ray diffraction, it has been reported that a hair from an individual with breast cancer exhibits a difference in its molecular structure compared to that of an individual without breast cancer. this difference is visible in the x-ray diffraction pattern as a ring superimposed on the pattern for normal hair. the hypothesis of this study is that synchrotron x-ray diffraction can be used to differentiate hairs from women with medically diagnosed breast cancer from women not known to have the disease. to test this hypothesis, hair from 2000 women attending radiology clinics for mammography will be collected, analysed by x-ray diffraction and then analysed using fermiscan proprietary image analysis software. the mammogram status of the subjects will be blinded from the diffraction analysts. results will then be compared with mammography results to allow a direct comparison between the fermiscan test and mammography in terms of specificity and sensitivity.


Eligibility criteria:
inclusion criteria: * adult women (aged \>20) who are undergoing mammography, and * who are willing and able to provide informed consent; and * who have usable scalp and/or pubic hair exclusion criteria: * women who have dyed or permed their scalp hair within the previous 6 weeks and whose pubic hair is unavailable; * women with a history of breast cancer ever or other cancers (excluding non-melanoma skin cancer and cin \[cervical intra-epithelial neoplasia\]) within 5 years.

Keywords: breast cancer diagnosis x-ray diffraction synchrotron hair
evaluation of laparotomy with trans-amniotic suture placement in ttts surgery

Conditions: Twin to Twin Transfusion Syndrome; Twin Anemia-Polycythemia Sequence

Summary: this is a randomized trial for patients that are diagnosed with twin-twin transfusion syndrome (ttts) who are receiving a fetoscopic laser surgery to evaluate the effectiveness and safety of a laparotomy closure.

the rationale behind suturing the hole is that the amniotic membrane does not close itself, rather you are relying that the uterus closes over the hole in the amniotic membrane, which may or may not happen, as well as in fetoscopic surgery for another condition, myelomeningocele. published data has shown that maternal laparotomy to suture closure of the port site at the time of fetoscopic surgery leads to improved pregnancy outcomes, later gestational age at delivery, and lower rates of preterm pre-labor rupture of membranes (pprom) \[pmid: 28910784\].

Eligibility criteria:
inclusion criteria: * diagnosis of ttts or twin anemia-polycythemia sequence (taps) * gestational age between 18 weeks and 23 weeks (18 0/7 to 22 6/7 weeks) * cervical length \>2.5 cm preoperatively * identification of a safe percutaneous surgical window by a provider experienced in fetoscopic surgery prior to entering the operating room exclusion criteria: * higher order pregnancies, chromosomal or severe congenital anomalies, undergoing laser surgery for fetal growth restriction only, need for a second laser during pregnancy, failure to complete laser, pprom prior to surgery. bmi\> 40 at the start of pregnancy, emergent case (i.e. surgery occurs \< 6 hours from presentation), significant fetal anomalies expected to drastically alter the risk of neonatal morbidity or mortality (i.e. anencephaly, cyanotic heart disease), or any significant maternal comorbidities as determined by physician i.e.: clotting disorders/blood disorders.

Keywords: fetoscopic surgery, laparotomy
safety and efficacy of prohema modulated umbilical cord blood units in subjects with hematologic malignancies.

Conditions: Hematologic Malignancies; Allogeneic Stem Cell Transplantation

Summary: the purpose of this research study is to determine the safety and efficacy of a reduced intensity conditioning regimen during a double umbilical cord blood unit transplant with one of the cord blood units modulated with prohema.

the purpose of this research study is to determine the safety and efficacy of a reduced intensity conditioning regimen during a double umbilical cord blood unit transplant with one of the cord blood units modulated with prohema. -as part of this research study cord units will be modulated in the laboratory with prohema before it is given to the participant. two different treatment groups will be tested. group 1: will have the second cord blood unit modulated with prohema; group 2: will have the first cord blood unit modulated with prohema.

Eligibility criteria:
inclusion criteria: * patients with hematologic malignancies for whom allogeneic stem cell transplantation is deemed clinically appropriate * patient must be ineligible for traditional myeloablative transplantation according to treating physician * lack of 6/6 or 5/6 hla-matched related, 8/8 hla-matched unrelated donor, or unrelated donor not available within a time frame necessary to perform a potentially curative stem cell transplant * 18-65 years of age * ecog performance status 0-2 exclusion criteria: * the following hematologic malignancies are excluded: * myelofibrosis unless there has been exposure to cytotoxic chemotherapy for the treatment of progression to acute myeloid leukemia * chronic myelogenous leukemia, unless there has been exposure to cytotoxic chemotherapy for the treatment of blast phase, 3) aplastic anemia, in the absence of transformation to myelodysplastic disorder * cardiac disease: symptomatic congestive heart failure or evidence of left ventricular dysfunction as measured by gated radionucleotide ventriculogram or echocardiogram; active angina pectoris, or uncontrolled hypertension * pulmonary disease: symptomatic chronic obstructive lung disease, symptomatic restrictive lung disease, or corrected dlco of \< 50% of predicted, corrected hemoglobin * renal disease: serum creatinine \> 2.0mg/dl * hepatic disease: serum bilirubin \> 2.0mg/dl (expect in the case of gilbert's syndrome or ongoing hemolytic anemia), sgot or sgpt \> 3 x upper limit of normal * neurologic disease: symptomatic leukoencephalopathy, active cns malignancy or other neuropsychiatric abnormalities believed to preclude transplantation * hiv antibody * uncontrolled infection * pregnancy or breast feeding mother * inability to comply with the requirements for care after allogeneic stem cell transplantation
physiotherapy treatment plan in allergic bronchopulmonary aspergillosis: case report

Conditions: Obstructive Pulmonary Disease

Summary: a spirometry study is performed in a patient diagnosed with allergic bronchopulmonary aspergillosis. an initial measurement is carried out and the patient is then put on a four-week physiotherapy treatment plan. four spirometry measurements were taken to assess different variables and an improvement in all the spirometry values was established.


Eligibility criteria:
inclusion criteria: * woman * diagnosis of respiratory insufficiency due to allergic bronchopulmonary aspergillosis * over 50 years of age * under 80 years of age exclusion criteria: * male * not have a diagnosis of respiratory insufficiency due to allergic bronchopulmonary aspergillosis * under 50 years of age * over 80 years of age

Keywords: obstructive pulmonary disease physiotherapy
clinical performance evaluation of two frequent replacement silicone hydrogel toric contact lenses

Conditions: Ametropia; Myopia; Hyperopia; Astigmatism

Summary: the primary objective of this study is to evaluate the axis orientation of lid226397 toric contact lenses.

subjects will be expected to attend 7 visits including a screening visit. the total duration of a subject's participation in the study will be approximately 40 days.

Eligibility criteria:
key inclusion criteria: * successful wearers of any commercial soft toric contact lenses (except aofahp and daily disposable lenses) in both eyes with at least 3 months wearing experience, with a minimum wearing time of 5 days per week and 10 hours per day. * able to be fit with and wear contact lenses within the available range of sphere \& cylinder power and axes. * best corrected distance visual acuity greater than or equal to 20/25 snellen (0.10 logmar) in each eye as determined by manifest refraction at screening. * other protocol-defined inclusion criteria may apply. key exclusion criteria: * wearing habitual contact lenses in an extended wear modality (routinely sleeping in lenses for at least 1 night per week) over the last 3 months prior to enrollment. * habitual aofahp contact lens wearers and habitual daily disposable lens wearers (worn within last 3 months). * other exclusion criteria may apply.
the effect of combined prp and eswt for carpal tunnel syndrome

Conditions: Carpal Tunnel Syndrome

Summary: the platelet rich plasma (prp) and extracorporeal shock wave therapy (eswt) are new and potential treatment for patients with kinds of musculoskeletal disorders. although few clinical studies have showed beneficial effect of prp and eswt for regeneration of peripheral neuropathy, the effect of combined prp and eswt is absent so far.

we perform a prospective randomized, double-blinded study to investigate the combined effect of prp and eswt in patients with carpal tunnel syndrome. patients were randomized into intervention and control group. participants in intervention group received sono-guided injection with 3cc prp and one-session active eswt and control group received sono-guided injection with 3cc prp and one-session sham eswt. the evaluation was performed pretreatment as well as on the 4th, 8th, 12th, 16th and 24 week after the treatment.

Eligibility criteria:
inclusion criteria: 1. age between 20-80 year-old. 2. typical symptoms and signs of cts, such as positive tinel's sign or phalen's test, numbness/tingling in at least two of the first, second, or third digits, and in whom the diagnosis was confirmed using an electrophysiological study. exclusion criteria: 1. cancer 2. coagulopathy 3. pregnancy 4. inflammation status 5. patients who had conditions mimicking cts, such as cervical radiculopathy, polyneuropathy, brachial plexopathy, thoracic outlet syndrome or who had previously undergone wrist surgery or steroid injection for cts.

Keywords: platelet rich plasma extracorporeal shock wave
comparative study of personality in parkinson's disease patients with other chronic pain

Conditions: Parkinson Disease

Summary: the present study compare personality of parkinson's disease (pd) patients with chronic, pd patients without pain and non-parkinsonian patients with other chronic pain condition.

the present study would like to compare personality dimensions from the temperament and character inventory (tci) in four groups of patients: pd patients with chronic pain related to pd, pd patients without pain and non-pd patients with chronic pain such as fibromyalgia or chronic headache. our aim is to evaluate if pd patients with chronic pain related to pd have a different personality than pd patients without pain and to see if this personality is specific to pd.

Eligibility criteria:
inclusion criteria: * pd patients: patients having parkinson's disease according to united kingdom parkinson's disease society brain bank (ukpdsbb) criteria pd patients with chronic pain: patients with a pain vas score ≥ 4 (mean vas for the last week) patients with a chronic pain since at least 3 months pd patients without pain: patients with a pain vas score \< 3 * non pd patients: patients with chronic headache: patients with chronic headache according to the ichd-3 beta criteria patients with a chronic pain since at least 3 months patients with fibromyalgia: patients with fibromyalgia according to the criteria of the american college of rheumatology 2016 (wolfe et al., 2016) patients with a pain vas score ≥ 4 (mean vas for the last week) patients with a chronic pain since at least 3 months * all patients: patient \> 18 years old patient able to give its free and informed consent patient having a social security. exclusion criteria: * pd patients: patients presenting atypical parkinson's syndrome patients having a deep brain stimulation patients presenting a cognitive decline evaluated by a montreal cognitive assessment (moca) score inferior to 24 * all patients: patient having a psychiatric disease diagnosed according to the diagnostic and statistical manual-v (dsm-v) criteria such as mood disorders, psychotic disorder... none ability to give its consent patients unable to realize the tests provided in the context of this study patients under supervision, curatorship, or legal guardian patients non-affiliated to a social security patients in exclusion period of another study.

Keywords: chronic pain personality
the prevalence of malocclusion development in a group of egyptian children with digit sucking aged 3 to 6 years

Conditions: Children With Digit Sucking

Summary: the purpose of the study is to determine the prevalence of malocclusion among a group of egyptian children with digit sucking aged 3 to 6 years.

the purpose of the study is to determine the prevalence of malocclusion among a group of egyptian children with digit sucking aged 3 to 6 years. pico: population: egyptian children with digit sucking aged 3 to 6 years. outcome: development of malocclusion.

Eligibility criteria:
inclusion criteria: * children between ages 3 to 6 years. * children those are medically free. * both genders are included. * egyptian children exclusion criteria: * history of an obvious alternative cause for malocclusion (e.g. trauma, syndromes). * participants exposed to thumb sucking prevention programs. * participants who underwent orthodontic treatment for his/her malocclusion. * participants' caregivers refuse to give consent.
cross-over study to evaluate the rate and the extent of iron absorption of an odf iron supplement vs an iron supplement in capsules

Conditions: Iron-deficiency

Summary: open, monocentric, comparative, cross-over study to evaluate the rate and the extent of iron absorption after a single oral dose of (a) ibsa iron orodispersible film vs (b) sideral® forte capsules in healthy women aged 18 to 55 years.

open, monocentric, comparative cross-over study to compare the rate and the extent of iron absorption after a single oral dose of (a) ibsa iron orodispersible film vs (b) sideral® forte capsules in healthy women aged 18 to 55 years. ibsa iron is a food supplement based on ferric pyrophosphate and folic acid in orodispersible film. sideral® forte is a preparation based on ferric pyrophosphate and vit.c in capsules. each subject will be observed for two consecutive days (phase i, day -1 and day 0) and after a 7-day washout (phase ii) for an additional two consecutive days (day -1 and day 0). half of the enrolled subjects will take a in phase i and b in phase ii; the remaining half of the enrolled subjects will take b in phase i and a in phase ii. in the two days (day -1 and day 0) of both phases, peripheral blood samples will be taken and the defined parameters, indicative of blood iron levels, will be measured. the primary endpoint is the auc0-t, tmax and cmax of serum iron. the secondary endpoints are the standard parameters indicative of blood iron levels.

Eligibility criteria:
inclusion criteria: * written informed consent signed prior to inclusion in the study; * women 18-55 years; * ability to understand the nature and the purpose of the study, including possible risks and side effects; * cability to collaborate with the investigator and meet the requirements of the entire study exclusion criteria: * smoke * clinically significant abnormalities in the ecg evaluation * clinically significant abnormal laboratory values indicative of disease * known allergy or presumed hypersensitivity to the food supplement investigated (iron) and / or to the excipients of the two formulations; * history of anaphylaxis from drugs, dietary supplements or allergic reactions in general, which the investigator believed could influence the outcome of the study * significant history of kidney, liver, gastrointestinal, cardiovascular, respiratory, skin, haematological, endocrine or neurological diseases that may interfere with the purpose of the study * taking herbal remedies and dietary supplements in the 2 weeks prior to the start of the study * taking corticosteroids, thyroid hormones, antibiotics, antiepileptics * alcohol abuse * any clinical condition that in the investigator's judgment is deemed incompatible with study participation * women who are pregnant or breastfeeding
a study to estimate the time course of pf-00241939 concentration in the blood after dosing with oral inhalation from dry powder inhalers

Conditions: Pharmacokinetics

Summary: the purpose of this study is to investigate the time course of pf-00241939 concentrations in the blood following dosing by oral inhalation using dry powder inhalers.


Eligibility criteria:
inclusion criteria: * healthy male and/or female subjects between the ages of 21 and 55 years. * body mass index (bmi) of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lbs). exclusion criteria: * evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing). * pregnant or nursing females. * a positive urine drug screen.